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Background:  Noroviruses  are  the  leading  cause  of  acute  gastroenteritis  and  foodborne  diarrheal  disease  in
the United  States.  Norovirus  vaccine  development  has progressed  in  recent  years,  but  critical  questions
remain  regarding  which  age  groups  should  be vaccinated  to maximize  population  impact.
Methods:  We  developed  a deterministic,  age-structured  compartmental  model  of  norovirus  transmission
and  immunity  in the  U.S.  population.  The  model  was  ﬁt  to  age-speciﬁc  monthly  U.S.  hospitalizations
between  1996  and  2007.  We  simulated  mass  immunization  of both  pediatric  and  elderly  populations
assuming  realistic  coverages  of  90%  and  65%,  respectively.  We  considered  two  mechanism  of  vaccine
action,  resulting  in  lower  vaccine  efﬁcacy  (lVE)  between  22%  and 43% and  higher  VE  (hVE)  of 50%.
Results:  Pediatric  vaccination  was  predicted  to avert  33%  (95%  CI: 27%, 40%)  and  60%  (95%  CI:  49%,  71%)
of  norovirus  episodes  among  children  under  ﬁve  years  for  lVE  and  hVE,  respectively.  Vaccinating  the
elderly  averted  17% (95%  CI:  12%,  20%)  and 38%  (95%  CI: 34%, 42%)  of cases  in  65+  year  olds  for  lVE  and
hVE,  respectively.  At  a population  level,  pediatric  vaccination  was  predicted  to avert  18–21  times  more
cases  and twice  as many  deaths  per  vaccinee  compared  to  elderly  vaccination.
Conclusions:  The  potential  beneﬁts  are  likely  greater  for  a  pediatric  program,  both  via direct  protection  of
vaccinated  children  and  indirect  protection  of unvaccinated  individuals,  including  adults  and  the  elderly.
These  ﬁndings  argue  for  a clinical  development  plan  that  will  deliver  a vaccine  with  a  safety  and  efﬁcacy
proﬁle  suitable  for use  in  children.
©  2016  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Noroviruses are the leading cause of acute gastroenteritis
n the United States, (Patel et al., 2008; Hall et al., 2013;
amani et al., 2014) responsible for an average 570–800 deaths,
6,000–71,000 hospitalizations, 400,000 emergency department
dmissions, 1.7–1.9 million outpatient admissions, and 19–21
illion illnesses annually (Hall et al., 2013). Severe norovirus out-
omes occur among pediatric and elderly populations, with 90% of
orovirus-associated deaths in the U.S. occurring among the elderly
∗ Corresponding author at: Department of Environmental Health, Rollins School
f  Public Health, 1518 Clifton Road, Atlanta, GA, United States.
E-mail address: molly.steele@emory.edu (M.K. Steele).
ttp://dx.doi.org/10.1016/j.epidem.2016.10.006
755-4365/© 2016 The Authors. Published by Elsevier B.V. This is an open access article 
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(Hall et al., 2012). Children under ﬁve years of age experience the
highest incidence (ﬁve times the general population) (Phillips et al.,
2010) and have the highest rates of outpatient, emergency depart-
ment, and inpatient visits (233, 38, and 9.4 per 10,000 persons per
year, respectively) (Lopman et al., 2011; Gastan˜aduy et al., 2013).
Given this substantial burden and limited options for prevention
and treatment, (CDC, 2011) vaccines are considered an important
means of providing protection from norovirus illness (Ramani et al.,
2014).
Safety, immunogenicity, and efﬁcacy studies on norovirus
vaccines have been encouraging, with at least one bivalent intra-
muscular product likely to progress to Phase III ﬁeld efﬁcacy trials
(Ramani et al., 2014). Current vaccine evaluations have been con-
ducted among adults. However, as noroviruses affect all ages and
are transmitted through multiple routes, an array of vaccination
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Fig. 1. Model schematic of the movement between six states of norovirus infection.
In  the absence of vaccination, persons are born directly into the susceptible pool
(S), become exposed at the force of infection ((t)), and then progress through the
exposed (E), symptomatic (I) and asymptomatic (A) stages at rates inversely pro-
portional to the duration of these states (, ϕ, ) before entering the recovered
compartment (R). From the recovered compartment, persons can become asymp-
tomatically infected at the force of infection or can become susceptible to disease
through the waning of natural immunity (). In the presence of a pediatric vaccina-
tion (panel A), a proportion of births entering the system will receive protection from
vaccines (v) and enter the vaccinated compartment (V). In the presence of elderly
vaccination (panel B), a proportion of the elderly will receive protection from vac-
cines (v) and enter the vaccinated compartment (V). Only children under ﬁve and
the elderly can ﬂow into vaccinated compartments. Under both pediatric and elderly
vaccine scenarios, vaccinated individuals can become asymptomatically infected at
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interpretations of vaccine-challenge studies. These studies sug-he force of infection or can become susceptible to disease through the waning of
accine immunity ().
trategies warrants consideration. At the current stage of vaccine
evelopment, the time is ideal for examining the population impact
hat various norovirus vaccination programs could have on the
ynamics of disease to guide vaccine development and inform pol-
cymakers on potential impacts.
Here, we present an age-structured dynamic transmission
odel to project the effects of different vaccination strategies on
he epidemiology and disease burden of norovirus in the U.S.,
ncluding the incidence of ﬁve clinical outcomes (cases, outpatient
isits, emergency department visits, inpatient visits, and deaths)
or each of four age classes (0–4, 5–17, 18–64, and 65+ years). The
odel was used to compare vaccination strategies targeting pedi-
tric versus elderly populations, both in terms of impact on disease
urden and relative efﬁciency under various assumptions about
accine efﬁcacy.
. Methods
We  adapted a previously-published, deterministic, age-
tructured compartmental model that simulates norovirus
ransmission and estimates disease incidence in the U.S. (Simmons
t al., 2013). The model follows a Susceptible-Exposed-Infected-
ecovered (SEIR-like) framework (Fig. 1, S1 Text). We  consider
our age classes: 0–4, 5–17, 18–64, and 65+ years old, and applied
ealistic, age-speciﬁc population sizes, aging and death rates, and
 heterogeneous contact structure (Table 1, S1 Text, Table S1).
acking detailed mixing data speciﬁc to the U.S., we used average
ontact patterns from representative samples of eight European
ountries in the POLYMOD study (Mossong et al., 2008).cs 17 (2016) 42–49 43
We estimated age-speciﬁc susceptibilities (qi) to allow the four
age classes (i; 0–4, 5–17, 18–64, and 65+ year olds) to exhibit
heterogeneous probabilities of infection given exposure to an infec-
tious contact. We  also considered models with different numbers
of estimated age-speciﬁc susceptibilities (qi) and where transmis-
sion was  dependent on susceptible or infectious individuals (S1
Text, Table S2); the results of this paper focus on the best-ﬁt
model, where the probabilities of infection on contact for 5–17 and
18–64 year olds were equal (q2 = q3).
We  assume maternal immunity is short-lived and negligible
(Gray et al., 1993). Therefore, absent vaccination, children are
born into the susceptible class (S). Susceptible individuals are
subjected to a force of infection (i(t)), and progress through pre-
symptomatic (E), symptomatic (I) and post-symptomatic (A) stages
at rates inversely proportional to the duration of incubation (),
symptomatic illness (ϕ), and asymptomatic shedding (), respec-
tively, before entering the recovered compartment (R). In this
framework, individuals acquire natural immunity that protects
against disease, but not against infection, until immunity wanes
(Phillips et al., 2010; Lindesmith et al., 2003). From the recovered
compartment, persons can become asymptomatically infected (A)
or susceptible to disease as natural immunity wanes (). To sim-
ulate seasonality, we applied a seasonal forcing parameter (ˇ1)
that governs the peak-to-mean amplitude in transmissibility. To
estimate clinical outcomes, we  multiplied the projected disease
incidence by age-speciﬁc probabilities (given norovirus illness) of
outpatient (OP) admission, emergency department (ED) admission,
hospitalization (IP), and death due to norovirus. These probabilities
were determined from U.S. population estimates and described in
more detail in previous work (Bartsch et al., 2012).
Model simulation, ﬁtting, and analysis were conducted in R ver-
sion 3.1.1. (R Core Team, 2016). Speciﬁc R packages used for these
analyses are detailed in the supplement. We ﬁt the model to age-
speciﬁc monthly counts of norovirus-associated hospitalizations
by maximum likelihood to estimate the susceptibility (q1...4) and
seasonality (ˇ1,ω) parameters (Lopman et al., 2011). We  assumed
the monthly numbers of hospitalizations in each age group were
Poisson distributed with mean equal to the model-predicted age-
speciﬁc incidence multiplied by the probability of hospitalization
(White et al., 2007). Age-speciﬁc R0 values were calculated follow-
ing procedures detailed in the supplement (S1 Text) and (Simmons
et al., 2013).
2.1. Vaccine scenarios
We assumed vaccine response was “take-type:” either pro-
tection against disease was  complete or vaccinated individuals
remained fully susceptible (Smith et al., 1984). We  assumed
vaccines confer protection in the same manner as we  conceptu-
alize natural immunity: providing protection against disease, but
not infection. Thus, vaccinated individuals can become asymp-
tomatically infected or susceptible to disease as vaccine-induced
immunity wanes () (Fig. 1).
After model ﬁtting, we  simulated routine, age-targeted vacci-
nation of infants around the time of birth with vaccine coverage
of 90% (i.e. Pediatric immunization) and individuals turning age
65 and every ﬁve years thereafter with vaccine coverage of 65%
(i.e. Elderly immunization). Vaccine coverage for these scenarios
was based on recent age-speciﬁc uptake of measles and inﬂuenza
vaccines (Annunziata et al., 2012; CDC, 2012; Lu et al., 2013). No
vaccine efﬁcacy (VE) estimates from ﬁeld trails exist for norovirus
vaccines, so we  considered two  different values, based on differentgest monovalent or bivalent norovirus vaccination followed by a
homotypic challenge reduces disease by approximately 50% among
vaccinated individuals (Bernstein et al., 2015; Atmar et al., 2011
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Table 1
Parameter input values, ranges tested in uncertainty analyses, and sources.
Parameter Symbol Input value Range (+/−
standard
deviation)
Distribution Source
Duration of incubation period  32.8 h (30.9–34.6) Uniform (Devasia et al., 2014)
Duration of symptomatic
infectiousness
ϕ 48 h (38.9–50.7) Uniform (Devasia et al., 2014)
Duration of asymptomatic
infectiousness
 10 days (1–20) Uniform (Atmar et al., 2008)
Duration of natural immunity  5.1 years (4.0–6.7) Uniform (Simmons et al., 2013)
Relative  infectiousness during
incubation and asymptomatic
period
ε 0.05 (0.045, 0.055) Uniform (Simmons et al., 2013)
Duration of vaccine
asymptomatic infectiousness
	 10 days (1–20) Uniform Assumed equal to duration of
natural infection
Duration of vaccine immunity  5.1 years (4.0–6.7) Uniform Assumed equal to duration of
natural immunity
OP  admission probability
0–4 years 0.168 (0.100–0.235) Uniform (Bartsch et al., 2012)
5–17  years 0.168 (0.111–0.226) Uniform (Bartsch et al., 2012)
18–64  years 0.06 (0.019–0.106) Uniform (Bartsch et al., 2012)
65+  years 0.103 (0.063–0.143) Uniform (Bartsch et al., 2012)
IP  admission probability
0–4 years 0.00428 +/− 0.000178 Normal (Bartsch et al., 2012)
5–17  years 0.00182 +/− 0.000074 Normal (Bartsch et al., 2012)
18–64  years 0.00228 +/− 0.000092 Normal (Bartsch et al., 2012)
65+  years 0.01733 +/− 0.000709 Normal (Bartsch et al., 2012)
Death  probability
0–4 years 0.00000625 +/− 2.57 × 10−7 Normal (Bartsch et al., 2012)
5–17  years 0.00000466 +/− 1.81 × 10−7 Normal (Bartsch et al., 2012)
18–64  years 0.00000466 +/− 1.81 × 10−7 Normal (Bartsch et al., 2012)
65+  years 0.000435 +/− 0.000018 Normal (Bartsch et al., 2012)
ED  visit probability
0–4 years 0.0179 (0.0112–0.0246) Uniform (Bartsch et al., 2012)
5–17  years 0.0199 (0.0114–0.0280) Uniform (Bartsch et al., 2012)
18–64  years 0.026 (0.0153–0.0368) Uniform (Bartsch et al., 2012)
65+  years 0.0325 (0.0199–0.0452) Uniform (Bartsch et al., 2012)
Fitted  Parameters
Susceptibility of 0–4 year olds q1 0.208 (0.141, 0.402)a – Estimated
Susceptibility of 5–17 and
18–64 year olds
q2,3 0.032 (0.023, 0.057)a – Estimated
Susceptibility of 65+ year olds q4 0.020 (0.014, 0.035)a – Estimated
Seasonal amplitude ˇ 0.034 (0.008, 0.089)a – Estimated
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Seasonal offset ω 2.147 
a Range in the ﬁtted value based on 1000 random samples of the ﬁxed paramete
tmar et al., 2011). In low-efﬁcacy vaccine scenarios (lVE Pediatric
nd Elderly) we assume only those immunologically susceptible
o norovirus at the time of vaccine administration gain additional
rotection from disease. About 44% and 55% of 0–4 year olds are sus-
eptible and recovered, respectively, prior to vaccination, resulting
n a VE around 22% for 0–4 year olds. In the elderly population, 85%
re susceptible and 14% are recovered prior to vaccination, thus VE
s approximately 43% for the elderly. Under a more optimistic high
E (hVE) scenario, we assume vaccination confers a 50% reduction
n disease incidence over one year among vaccinated individuals.
For these four vaccine scenarios—and for a scenario with-
ut vaccination—we estimated age-speciﬁc incidence of disease
nd clinical outcomes. Analyses of long-term impacts of vaccina-
ion were conducted after the system had reached equilibrium,
pproximately 40 years after vaccine introduction. We  simulated
 well-established vaccination program with coverage similar to
ther vaccines. More detailed analysis are required to model the
cale-up of vaccine coverage in the ﬁrst few years after implemen-
ation and the associated epidemiological impacts. We  calculated
opulation direct and indirect effects of vaccination by comparing
accine to no-vaccine simulations. We  also assessed the efﬁciency
f vaccine simulations, deﬁned as the number of clinical outcomes
verted per vaccinee (S1 Text).961, 2.266)a – Estimated
2.2. Parameters and simulations
Parameter values (and ranges) for natural history, and clinical
outcome probabilities were set to values identiﬁed in observa-
tional/challenge studies, and previous modeling studies (Table 1).
We used Latin hypercube sampling to generate 1100 random sam-
ples of parameter sets and then re-ﬁt the transmission probabilities
and seasonality parameters, in the absence of vaccination, for each
parameter set. We  then ranked the 1100 sampled and ﬁtted param-
eter sets by their negative log likelihood (NLL) value. The 100
parameter sets with the highest NLL values were discarded, and we
ran each vaccine scenario with the remaining 1000 parameter sets.
For summary statistics, we report medians and 2.5/97.5 percentiles
of the annual clinical outcomes averted. These annual data are four
year averages. In order to quantify the sensitivity of model projec-
tions to uncertainty in each parameter’s value, we calculated partial
rank correlation coefﬁcients (PRCC) for natural history and vaccine
parameters. PRCC values were calculated between model param-
eters and the percentage of cases averted in the total population
and the age group targeted for vaccination in a given vaccination
scenario.
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Fig. 2. Age-speciﬁc observed and predicted in best ﬁtting model of hospitalizations
per year in the United States. The error bars in the observed data represent the range
in  annual hospitalizations over the 11 year data set. The error bars on the model data
represent the range in annual hospitalizations based on the range in estimated and
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(Table S4, Figs. 4D, 5D).
F
oatural history parameter values identiﬁed in Table 1.
. Results
.1. Model ﬁtting
The best ﬁt model based on the minimum Akaike informa-
ion criterion (Table S2) included three age-speciﬁc probabilities of
nfection on contact. The observed and predicted average annual
orovirus hospitalizations were 71,461 and 71,906, respectively
Fig. 2). A seasonal forcing of 3.4% (95% CI: 1.1%, 8.1%) of peak-
o-mean amplitude provided the best ﬁt to observed seasonal
ariation in monthly hospitalizations (Table 1, Fig. S2, Table S2).
n the best-ﬁt model, 0–4 year olds contributed the most to trans-
ission, with an age-speciﬁc basic reproduction number (R0) of
.3 compared to 1.4, 1.2, and 0.4 from 5–17, 18–64, and 65+ years,
espectively (S1 Text).
ig. 3. Predicted incidence of disease within the age-group targeted for vaccination over ti
lds.  (B) Impact of the Elderly vaccine programs on incidence of disease in 65 year olds ancs 17 (2016) 42–49 45
3.2. Vaccine impact
The Pediatric programs rapidly reduced disease incidence in
0–4 year olds. Disease incidence exhibited inter-annual variability
for the ﬁrst several years before reaching lower equilibria (Fig. 3A).
In the ﬁrst ﬁve years of the lVE Pediatric program, incidence among
0–4 year olds was  reduced by 24%, 41%, 22%, 37%, and 30%. In
the ﬁrst ﬁve years of the hVE Pediatric program, incidence among
0–4 year olds was  reduced by 42%, 78%, 59%, 46%, and 68%.
Elderly vaccination led to gradual reductions in disease inci-
dence, achieving a new equilibrium of lower incidence in
approximately 15 years (Fig. 3B). In the ﬁrst ﬁve years of the lVE
Elderly program, incidence among the elderly was reduced by 3%,
6%, 9%, 11%, and 12%. In the ﬁrst ﬁve years of the hVE Elderly pro-
gram, incidence among the elderly was reduced by 5%, 13%, 19%,
23%, and 26%.
The lVE Pediatric program at equilibrium was  predicted to avert
33% (95% CI: 27%, 40%) of all clinical outcomes in 0–4 year olds
annually (Table 2, Figs. 4A, 5A ). Approximately 71% of the averted
outcomes were achieved through direct effects and 29% through
indirect effects (Fig. 4A). In older age classes, 14–16% of cases were
averted primarily through indirect effects (Figs. 4A, 5A, Table 2).
The hVE Pediatric program at equilibrium was predicted to avert
60% (95% CI: 49%, 71%) of all clinical outcomes among 0–4 year olds
annually (75% through direct and 25% indirect protection; Table
S3, Figs. 4C, 5C). In older age classes, 29–33% of cases were averted
primarily through indirect protection (Table S3, Figs. 4C, 5C).
A lVE Elderly program at equilibrium would avert approximately
17% (95% CI: 12%, 20%) of all clinical outcomes almost exclusively
through direct effects in the elderly (Table 3, Figs. 4B, 5B). Mini-
mal  impacts were conferred on other age groups as less than 1% of
outcomes in 0–64 year olds were averted through indirect effects
(Table 3, Figs. 4B, 5B).
The hVE Elderly program at equilibrium was predicted to avert
38% (95% CI: 34%, 42%) of all clinical outcomes in the elderly almost
exclusively through direct effects (Table S4, Figs. 4D, 5D).  Minimal
impacts were conferred on younger age groups, with approxi-
mately 1% or less of outcomes averted through indirect effectsPediatric programs were more efﬁcient than Elderly programs.
Per 100,000 vaccinees assuming lVE, the Pediatric program averted
me. (A) Impact of the Pediatric vaccine programs on incidence of disease in 0–4 year
d older.
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Table 2
Outcomes averted (95% CI) annually with a pediatric vaccine program with vaccine coverage of 90% and vaccine efﬁcacy of 22% (lVE Pediatric).
Age Group Cases Averted Outpatients Averted ED Visits Averted Hospitalizations Averted Deaths Averted
0–4 years 1,430,000 237,000 25,700 6200 9
(1,185,000, 1,724,000) (141,000, 356,000) (15,700, 37,500) (5100, 7400) (7, 11)
5–17  years 419,000 69,000 8100 800 2
(219,000, 705,000) (32,000, 132,000) (3500, 16,400) (400, 1300) (1, 3)
18–64  years 1,157,000 70,000 30,000 2600 5
(701,000, 1,876,000) (22,000, 160,000) (14,900, 58,400) (1600, 4300) (3, 9)
65+  years 266,000 27,000 8500 4600 115
(173,000, 410,000) (14,000, 49,000) (4600, 15,500) (3000, 7000) (75, 180)
Total  (#) 3,282,000 407,000 72,400 14,200 132
(2,295,000, 4,720,000) (259,000, 614,000) (45,900, 115,700) (10,100, 20,100) (87, 202)
Total  (%) 19% 22% 18% 20% 16%
(13%, 27%) (15%, 30%) (12%, 26%) (14%, 28%) (11%, 25%)
Table 3
Outcomes averted (95% CI) with routine elderly immunization with vaccine coverage of 65% and vaccine efﬁcacy of 43% (lVE Elderly).
Age Group Cases Averted Outpatients Averted ED Visits Averted Hospitalizations Averted Deaths Averted
0–4 years 8500 1400 150 36 0.05
(4700, 14,800) (630, 2800) (70, 290) (19, 65) (0.03, 0.09)
5–17  years 9200 1500 180 17 0.04
(5400, 15,400) (760, 2900) (80, 370) (10, 28) (0.03, 0.07)
18–64  years 42,300 2500 1100 100 0.20
(25,700, 65,900) (810, 5600) (530, 2100) (60, 150) (0.12, 0.31)
65+  years 276,900 28,100 8800 4800 120
(204,700, 344,400) (16,100, 43,400) (5100, 13,700) (3600, 5800) (88, 151)
Total  (#) 336,900 33,800 10,200 4900 120
(240,300, 436,500) (20,100, 50,900) (6100, 15,600) (3700, 6000) (88, 151)
Total  (%) 1.9% 1.8% 2.5% 6.9% 15%
(1.4%,  2.5%) (1.1%, 2.9%) (1.6%, 3.7%) (5.1%, 8.5%) (11%, 18%)
Table 4
Clinical outcomes averted per 100,000 vaccinees (95% CI) over 1 year.
Vaccine strategy Cases averted per
100,000 doses
Outpatient visits
averted per
100,000 doses
ED visits averted
per 100,000
doses
Hospitalizations
averted per
100,000 doses
Deaths averted
per 100,000
doses
lVE Pediatric
0–4 years 39,500 6600 710 170 0
(32,700, 47,600) (3900, 9800) (430, 1040) (140, 200) (0, 0)
Total 90,600 11,200 2000 390 4
(63,400, 130,300) (7100, 16,900) (1270, 3200) (280, 560) (2, 6)
lVE  Elderly
65+ years 3500 360 110 61 2
(2600, 4400) (210, 560) (66, 170) (46, 74) (1, 2)
Total 4300  430 130 63 2
(3100, 5600) (260, 650) (80, 200) (50, 80) (1, 2)
hVE  Pediatric
0–4 years 72,400 11,900 1280 310 0
(58,800, 87,000) (7100, 18,000) (790, 1920) (250, 370) (0, 1)
Total 178,000 21,400 3940 760 7
(119,400, 256,200) (13,000, 33,400) (2450, 6340) (530, 1070) (5, 11)
hVE  Elderly
65+ years 8100 840 270 141 4
(7100, 9400) (510, 1200) (160, 380) (120, 160) (3, 4)
10 
0) 
2
E
(
a
mTotal 9900  10
(8400, 12,000) (600, 140
1 times more cases; 26 times more OP visits; 15 times mores
D visits; 6 times more IP admissions; and twice as many deaths
Table 4) as Elderly programs. For hVE, the Pediatric programs
verted 18 times more cases; 21 times more OP visits; 13 times
ore ED visits; 5 times more IP admissions; and twice as many310 145 4
(200, 430) (130, 160) (3, 4)
deaths (Table 4) as Elderly programs. For every one case averted
through direct effects, 3 and 5 cases in the total population were
averted through indirect effects with lVE and hVE Pediatric pro-
grams, respectively. For every one case averted through direct
M.K. Steele et al. / Epidemi
Fig. 4. Direct (blue) and indirect effects (yellow) of each vaccine scenario (A) Low
vaccine efﬁcacy (lVE) Pediatric program (B) Low vaccine efﬁcacy (lVE) Elderly pro-
gram (C) High vaccine efﬁcacy (hVE) Pediatric program (D) High vaccine efﬁcacy
(hVE) Elderly program. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
Fig. 5. Boxplots representing the range of uncertainty in the percent of cases averted
over a one year time period, given uncertainty in parameter input values (A) Low
vaccine efﬁcacy (lVE) Pediatric program (B) Low vaccine efﬁcacy (lVE) Elderly pro-
gram (C) High vaccine efﬁcacy (hVE) Pediatric program (D) High vaccine efﬁcacy
(hVE) Elderly program.
e
i
vaccine studies have included long-term follow-up for clinical out-
comes (Treanor et al., 2014). In order to better predict the impacts
of norovirus vaccines in future work, this analysis highlights the
high value of collecting information on transmission from obser-ffects, 0.5 and 1 cases in the total population were averted through
ndirect effects with lVE and hVE Elderly programs, respectively.cs 17 (2016) 42–49 47
3.3. Sensitivity Analysis
For the Pediatric vaccine programs, the duration of natural
immunity (), duration of vaccine induced immunity (), and the
probability of infection on contact for 5–64 year olds (q2,3) had the
most inﬂuence on the percent of cases averted in the total popu-
lation (Table 5). The most inﬂuential parameters on the percent
of cases averted in the total population for the Elderly vaccine
programs were the duration of natural immunity (), duration of
vaccine induced immunity (), and the probability of infection on
contact for 65+ year olds (q4) (Table 5).
When other parameters were ﬁxed, the percentage of cases
averted in the total population ranged from 15% (95% CI: 12%, 20%)
to 23% (95% CI: 18%, 30%) and 28% (95% CI: 22%, 39%) to 45% (95%
CI: 34%, 60%) across the tested range in duration of vaccine immu-
nity (Table 1) for lVE and hVE Pediatric programs, respectively. The
percentage of cases averted in the total population ranged from 1%
(95% CI: 1%, 2%) to 2% (95% CI: 2%, 3%) and 4% (95% CI: 3%, 5%) to
5% (95% CI: 4%, 6%) across the tested range in duration of vaccine
immunity for lVE and hVE Elderly programs, respectively.
4. Discussion
Results from this transmission modeling study suggest the
overall population impact of norovirus vaccination can vary sub-
stantially depending on the age group targeted. Pediatric programs
offered the greatest reductions in all clinical outcomes, with 33% to
60% decreases among 0–4 year olds, and 14% to 33% reductions in
older age groups achieved primarily through indirect protection.
Pediatric programs were 18–21 times more efﬁcient at prevent-
ing cases and 5–6 and two times more efﬁcient at preventing IP
admissions, and deaths, respectively, when compared to Elderly
programs. Elderly programs averted between 17% and 38% of cases
in the elderly, and provided protection almost exclusively through
direct effects. This is a result of the minimal contribution that the
elderly make to disease transmission. In fact, Pediatric programs
were predicted to confer similar beneﬁts to the elderly as Elderly
programs. Taken together, these results indicate targeting pediatric
populations for vaccination leads to greater direct and indirect ben-
eﬁts for the total population than vaccine programs that target the
elderly. Children under ﬁve have higher disease, OP, and ED admis-
sion rates; thus vaccines can directly prevent these outcomes. The
indirect beneﬁts of Pediatric programs are a result of reductions
in disease transmission, owing to the importance of young chil-
dren in transmission. This ﬁnding is consistent with observational
studies that identiﬁed contact with a young child with norovirus
gastroenteritis as a risk factor for diarrhea for older children and
adults (Phillips et al., 2010; de Wit  et al., 2001). Large indirect bene-
ﬁts have been observed with the introduction of pediatric rotavirus
and pneumococcal vaccines in the U.S., with unvaccinated popula-
tions protected through reductions in the overall force of infection
(Tate et al., 2011; Lexau et al., 2005).
A second important ﬁnding was  the identiﬁcation of key
parameters that inﬂuence the impact of vaccination programs.
For both Pediatric and Elderly vaccination programs, the dura-
tion of vaccine-induced immunity, and age-speciﬁc transmission
parameters (q2,3 and q4 for Pediatric and Elderly programs, respec-
tively) strongly determined the outcome of the analysis. These
are parameters for which we  have limited empirical data because
transmission is largely unobservable (Sukhrie et al., 2012), and no
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Table 5
Partial rank correlation coefﬁcients (PRCC) between selected model parameters and the percent of cases averted in the total population for each of four vaccination strategies.
Symbol lVE lVE hVE hVE
Pediatric Elderly Pediatric Elderly
Natural History Parameters
 0.04 0.06 0.03 0.07
ϕ  −0.19 0.11 −0.15 0.21
  0.19 0.11 0.19 0.14
  −0.84 (2)a −0.66 (3)a −0.81 (2)a −0.57 (3)a
ε −0.09 −0.02 −0.06 0.03
q1 0.04 −0.35 0.10 −0.37
q2,3 −0.41 (3)a −0.41 −0.37 (3)a −0.44
q4 0.35 0.82 (2)a 0.31 0.87 (2)a
Vaccine Parameters
 0.94 (1)a 0.97 (1)a 0.94 (1)a 0.90 (1)a
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a The top 3 most inﬂuential parameters for each vaccine program are indicated b
ational studies and conducting clinical trials that can estimate the
uration of protection for both children under ﬁve and the elderly.
The predicted impacts of lVE scenarios were modest due to tech-
ical reasons related to our model construction. First, we  assume
accination only provides additional protection for those who  are
usceptible to disease (in the S class) at the time of immuniza-
ion. Individuals who have acquired natural immunity will receive
o added protection. This assumption strongly limits the impact
f vaccination for adults as many will have acquired immunity,
hereas we assume all children are susceptible at the time of infant
mmunization. A second explanation is that we assume exponen-
ial waning of both natural and vaccine immunity; thus while the
verage duration of protection is 5.1 years, most individuals have
 shorter-duration immunity while a few have longer-term pro-
ection. Compartmental models can be modiﬁed to assume other
istributions for waning immunity; however no data are available
o inform the functional form of waning immunity to norovirus.
he hVE scenarios which were based on a 50% vaccine efﬁcacy
Bernstein et al., 2015; Atmar et al., 2011 Atmar et al., 2011) resulted
n more optimistic impacts. The values and concepts of vaccine
ction that are most appropriate can be informed by future clinical
rial data.
There are several limitations to this study. First, there is uncer-
ainty in the robustness of the epidemiological data used to ﬁt
he model. We  used U.S. hospitalization data, which are model
stimates, and community incidence rates were informed by a
.K. study. In that study, incidence in older age groups was low
nd may  have been biased downwards (Phillips et al., 2010). Fit-
ing to such low incidence limited the potential impact of elderly
mmunization in our model and limited the role of elderly peo-
le in transmission. Second, there is considerable uncertainty in
odel parameters due to our limited understanding of natural his-
ory of norovirus disease and transmission, particularly the relative
oles of pre- and post-symptomatic transmission. Third, our model
onstruction assumes a single strain of norovirus; thus infection
rom, or vaccination against, one strain of norovirus provides pro-
ection against all other infections. This is a major simpliﬁcation,
s noroviruses are highly genetically diverse and natural immu-
ity provides only limited cross-protection within genogroups
Wyatt et al., 1974). However, this simpliﬁcation may  be partially
ccounted for by the duration of immunity parameter, particularly
n the low vaccine efﬁcacy scenario. In addition, novel genogroup
 type 4 (GII.4) strains emerge every two to four years, that may
vade host population immunity. Current data are insufﬁcient to
stablish the degree of cross-protection to norovirus, or to param-
terize a multi-strain model as has been accomplished for inﬂuenza
Arinaminpathy et al., 2012). For a more complete understanding of
orovirus transmission and vaccination, these are important areas−0.25 −0.11
s in parentheses.
for further empirical studies and, subsequently, model develop-
ment. Additionally, we did not consider a model that incorporated
a class of individuals that are genetically resistant to norovirus
infection. As more data become available on the effect of vacci-
nation among genetically resistant individuals, future modeling
studies should consider such a class. Another important limitation
is that we  assumed that VE was the same for all clinical outcomes
and disease severity. This may  not be the case. For rotavirus, VE
is greater for severe outcomes (Tate et al., 2011). Finally, while
we developed a model to predict the impact of infant and elderly
vaccination, there have been no studies of VE in pediatric popula-
tions and only one immunogenicity study in the elderly (Treanor
et al., 2014). Human safety, immunogenicity and efﬁcacy studies
have all involved experimental challenge of adults (typically 18–49
years old) (Bernstein et al., 2015; Atmar et al., 2011; El-Kamary
et al., 2010). While these results are promising, clinical trials will
be pivotal in determining VE among infants and the elderly. Though
our study made several simplifying assumptions—as all models
do—the dynamic transmission framework presented here offers a
more comprehensive understanding of total population beneﬁts of
vaccination than previous studies that included only direct effects
(Bartsch et al., 2012).
In summary, our results quantitatively demonstrate that the
potential public health value of a norovirus vaccine is likely great-
est with pediatric immunization. This ﬁnding argues for a clinical
development plan for a vaccine with a safety and efﬁcacy proﬁle
suitable for use in children. To improve models for future analy-
ses, better data are needed on the duration of natural and vaccine
immunity, the extent of cross-protection and process of norovirus
infection. Future modeling studies should incorporate norovirus
strain diversity to examine the implications of multiple, evolv-
ing strains for vaccination. As more data become available on the
extent of cross-protection and the duration of vaccine immunity,
this modeling framework can be adapted to more precisely esti-
mate population-level impacts of norovirus vaccination. Models
should also be adapted to developing world settings where the
force of infection is higher (Shioda et al., 2015) and disease burden
is greater (Ahmed et al., 2014).
5. Funding
This work was  supported by a NoroCORE Graduate Fellowship
funded by the United States Department of Agriculture - National
Institute of Food and Agriculture Food Virology Collaborative [to
MKS]; a fellowship from the Oak Ridge Institute for Science and
Education [to MKS]; the National Institutes of Health/National
Institute of Allergy and Infectious Diseases[K01AI091864 to JVR];
the National Science Foundation Water Sustainability and Cli-
idemi
m
H
f
c
C
D
a
C
o
A
t
0
R
A
A
A
A
A
B
B
C
C
d
DM.K. Steele et al. / Ep
ate Program [1360330 to JVR]; and the National Institutes of
ealth/Fogarty International Center [R01TW010286 to JVR]. The
unding sources for this study had no role in the study design, data
ollection, analysis, interpretation, or writing the report.
onﬂicts of interest
None.
isclaimer
The ﬁndings and conclusions in this report are those of the
uthors and do not necessarily represent the ofﬁcial position of the
enters for Disease Control and Prevention, or the US Department
f Health and Human Services.
ppendix A. Supplementary data
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.epidem.2016.10.
06.
eferences
hmed, S.M., et al., 2014. Global prevalence of norovirus in cases of gastroenteritis:
a  systematic review and meta-analysis. Lancet Infect. Dis. 14, 725–730.
nnunziata, K., Rak, A., Del Buono, H., DiBonaventura, M.,  Krishnarajah, G., 2012.
Vaccination rates among the general adult population and high-risk groups in
the  United States. PLoS One 7.
rinaminpathy, N., et al., 2012. Impact of cross-protective vaccines on
epidemiological and evolutionary dynamics of inﬂuenza. Proc. Natl. Acad. Sci.
109, 3173–3177.
tmar, R.L., et al., 2008. Norwalk virus shedding after experimental human
infection. Emerg. Infect. Dis. 14, 1553–1557.
tmar, R.L., et al., 2011. Norovirus vaccine against experimental human Norwalk
Virus illness. N. Engl. J. Med. 365, 2178–2187.
artsch, S.M., Lopman, B.A., Hall, A.J., Parashar, U.D., Lee, B.Y., 2012. The potential
economic value of a human norovirus vaccine for the United States. Vaccine
30, 7079–7104.
ernstein, D.I., Atmar, R.L., Lyon, G.M., Treanor, J.J., Chen, W.H., Jiang, X., Vinjé, J.,
Gregoricus, N., Frenck, R.W., Moe, C.L., Al-Ibrahim, M.S., Barrett, J., Ferreira, J.,
Estes, M.K., Graham, D.Y., Goodwin, R., Borkowski, A., Clemens, R., Mendelman,
P.M., 2015. Norovirus vaccine against experimental human GII. 4 virus illness:
A challenge study in healthy adults. J. Infect. Dis. 211, 870–878.
enters for Disease Control and Prevention, 2011. Updated norovirus outbreak
management and disease prevention guidelines. Morb. Mortal. Wkly. Report,
Recomm. Rep. 60, 1–18.
enters for Disease Control and Preventon (CDC), 2012. National, state, and local
area vaccination coverage among children aged 19–35 months–United States.
Morb. Mortal. Wkly. Rep. 61, 689–696.
e Wit, M.,  et al., 2001. Sensor, a population-based cohort study on
gastroenteritidis in the Netherlands: incidence and etiology. Am.  J. Epidemiol.
154, 666–6 666–674.
evasia, T., Lopman, B., Leon, J., Handel, A., 2014. Association of host, agent and
environment characteristics and the duration of incubation and symptomatic
periods of norovirus gastroenteritis. Epidemiol. Infect., 1–7, FirstView.cs 17 (2016) 42–49 49
El-Kamary, S.S., et al., 2010. Adjuvanted intranasal Norwalk virus-like particle
vaccine elicits antibodies and antibody-secreting cells that express homing
receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis 202,
1649–1658.
Gastan˜aduy, P.A., Hall, A.J., Curns, A.T., Parashar, U.D., Lopman, B.A., 2013. Burden
of  norovirus gastroenteritis in the ambulatory setting – United States,
2001–2009. J. Infect. Dis. 207, 1058–1065.
Gray, J.J., Jiang, X., Morgan-Capner, P., Desselberger, U.,  Estes, M.K., 1993.
Prevalence of antibodies to Norwalk virus in England: detection by
enzyme-linked immunosorbent assay using baculovirus-expressed Norwalk
virus capsid antigen. J. Clin. Microbiol. 31, 1022–1025.
Hall, A.J., Curns, A.T., McDonald, L., Parashar, U.D., Lopman, B.A., 2012. The roles of
clostridium difﬁcile and norovirus among gastroenteritis- associated deaths in
the United States, 1999–2007. Clin. Infect. Dis. 55, 216–223.
Hall, A.J., et al., 2013. Norovirus disease in the United States. Emerg. Infect. Dis. 19,
1198–1205.
Lexau, C.A., et al., 2005. Changing epidemiology of invasive pneumococcal disease
among older adults in the era of pediatric pneumococcal conjugate vaccine.
JAMA 294, 2043–2051.
Lindesmith, L., et al., 2003. Human susceptibility and resistance to Norwalk virus
infection. Nat. Med. 9.
Lopman, B.A., Hall, A.J., Curns, A.T., Parashar, U.D., 2011. Increasing rates of
gastroenteritis hospital discharges in US adults and the contribution of
norovirus, 1996–2007. Clin. Infect. Dis. 52, 466–474.
Lu, P., Santibanez, T.A., Williams, W.W.,  Zhang, J., Ding, H., Bryan, L., O’Halloran, A.,
Greby, S.M., Bridges, C.B., Graitcer, S.B., Kennedy, E.D., Lindley, M.C., Ahluwalia,
I.B., LaVail, K., Pabst, L.J., Harris, L., Vogt, T., Town, M.,  Singleton, J.A., 2013.
Surveillance of inﬂuenza vaccination coverage’ United States, 2007–08
through 2011–12 inﬂuenza seasons. MMWR.  Surveill. Summ. 62, 1–28,
doi:ss6204a1 [pii].
Mossong, J., et al., 2008. Social contacts and mixing patterns relevant to the spread
of infectious diseases. PLoS Med. 5, e74.
Patel, M.M., et al., 2008. Systematic literature review of role of noroviruses in
sporadic gastroenteritis. Emerg. Infect. Dis. 14, 1224–12231.
Phillips, G., et al., 2010. Community incidence of norovirus-associated infectious
intestinal disease in England: improved estimates using viral load for
norovirus diagnosis. Am.  J. Epidemiol. 171, 1014–1022.
R Core Team, 2016. R. A language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria http://www.r-project.
org.
Ramani, S., Atmar, R.L., Estes, M.K., 2014. Epidemiology of human noroviruses and
updates on vaccine development. Curr. Opin. Gastroenterol. 30, 25–33.
Shioda, K., Kambhampati, A., Hall, A.J., Lopman, B.A., 2015. Global age distribution
of  pediatric norovirus cases. Vaccine, 3–6, http://dx.doi.org/10.1016/j.vaccine.
2015.05.051.
Simmons, K., Gambhir, M.,  Leon, J., Lopman, B., 2013. Duration of immunity to
norovirus gastroenteritis. Emerg. Infect. Dis. 19, 1260–1267.
Smith, P.G., Rodrigues, L.C., Fine, P.E.M., 1984. Assessment of the protective efﬁcacy
of  vaccines against common diseases using case-control and cohort studies.
Int. J. Epidemiol. 13.
Sukhrie, F.H., et al., 2012. Nosocomial transmission of norovirus is mainly caused
by  symptomatic cases. Clin. Infect. Dis. 54, 931–937.
Tate, J.E., et al., 2011. Uptake, impact, and effectiveness of rotavirus vaccination in
the United States: review of the ﬁrst 3 years of postlicensure data. Pediatr.
Infect. Dis. J. 30, S56–S60.
Treanor, J.J., et al., 2014. A novel intramuscular bivalent norovirus virus-like
particle vaccine candidate–reactogenicity, safety, and immunogenicity in a
phase 1 trial in healthy adults. J. Infect. Dis. 210, 1763–1771.
White, L.J., et al., 2007. Understanding the transmission dynamics of respiratory
syncytial virus using multiple time series and nested models. Math. Biosci. 209,
222–239.
Wyatt, R.G., et al., 1974. Comparison of three agents of acute infectious
nonbacterial gastroenteritis by cross-challenge in volunteers. J. Infect. Dis. 129,
709–714.
